Producer
CollPlant Biotechnologies
Engineers transgenic tobacco plants with five human genes (COL1A1, COL1A2, and three hydroxylase/chaperone genes) to produce recombinant human Type I collagen structurally identical to endogenous human collagen. Zero prion risk, zero animal allergens, no halal/kosher compliance issue. 2024 revenue USD 515K (early commercial stage); Vergenix STR wound product commercial. NASDAQ-listed.
0
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.